Abstract / Summary
Tumor necrosis factor-α inhibitors (anti-TNF-α) and mesenchymal stem cells (MSCs) have been proven to be effective for Perianal fistulizing Crohn's disease (PFCD). However, no head-to-head clinical trials have directly comparing these two therapies. Therefore, using a network meta-analysis and systematic review, we evaluated the efficacy and safety of anti-TNF-α and MSCs in PFCD patients. We included randomized controlled trials (RCTs) evaluating anti-TNF-α or MSCs against placebo (PBO) in PFCD patients. The primary efficacy outcomes were fistula remission and fistula response. The secondary outcome was clinical remission. Safety outcomes comprised adverse events and infections. Effect sizes were reported as odds ratios (ORs) with 95% credible intervals (CrIs). Treatment rankings were determined using the surface under the cumulative ranking curve (SUCRA). A total of 15 RCTs involving 2, 475 patients were included. Compared with PBO, MSCs significantly improved fistula remission (OR = 5.33, 95% CrI: 2.19-19.03) and fistula response (OR = 4.76, 95% CrI: 1.78-20.37). Anti-TNF-α also significantly increased fistula remission rates (OR = 2.19, 95% CrI: 1.01-4.54). SUCRA rankings placed MSCs first for both fistula remission (SUCRA = 0.97) and fistula response (SUCRA = 0.967). For clinical remission, anti-TNF-α demonstrated superior efficacy (OR = 2.41, 95% CrI: 1.30-5.03) compared with MSCs (OR = 1.71, 95% CrI: 0.69-5.57) and PBO. Indirect comparisons revealed a non-significant trend favoring MSCs over anti-TNF-α for fistula remission (OR = 2.44) and fistula response (OR = 2.55). Neither treatment showed statistically significant differences in adverse events or infections versus PBO, indicating favorable safety profiles for both. In indirect comparisons, MSCs showed a numerically greater but not statistically significant effect on fistula healing compared with anti-TNF-α, whereas anti-TNF-α was superior for clinical remission. Both treatments were generally safe. Given the indirect nature of these comparisons, direct head-to-head trials are needed to establish their comparative efficacy. https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD42021283052.